Neonatal diabetes mellitus: a model for personalized medicine.

Article Details

Citation

Copy to clipboard

Greeley SA, Tucker SE, Naylor RN, Bell GI, Philipson LH

Neonatal diabetes mellitus: a model for personalized medicine.

Trends Endocrinol Metab. 2010 Aug;21(8):464-72. doi: 10.1016/j.tem.2010.03.004. Epub 2010 Apr 29.

PubMed ID

20434356 [ View in PubMed

]

Abstract

Neonatal diabetes mellitus occurs in approximately 1 out of every 100,000 live births. It can be either permanent or transient, and recent studies indicate that is likely to have an underlying genetic cause, particularly when diagnosed before 6 months of age. Permanent neonatal diabetes is most commonly due to activating mutations in either of the genes encoding the two subunits of the ATP-sensitive potassium channel. In most of these patients, switching from insulin to oral sulfonylurea therapy leads to improved metabolic control, as well as possible amelioration of occasional associated neurodevelopmental disabilities. It remains to be determined what is the most appropriate treatment of other causes. The diagnosis and treatment of neonatal diabetes, therefore, represents a model for personalized medicine.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Glymidine	ATP-sensitive inward rectifier potassium channel 1	Protein	Humans	Yes	Other/unknown	Details